RELEASE OF MAIZE [ZEA MAYS L. (WALP.)] OPEN-POLLINATED CULTIVAR MAYORBELA 05

RELEASE OF MAIZE [ZEA MAYS L. (WALP.)] OPEN-POLLINATED CULTIVAR MAYORBELA 0

Grappling with Chronic Pain and Poverty during the COVID-19 Pandemic

Joel Katz is supported by a Canadian Institutes of Health Research Canada Research Chair in Health Psychology at York University. Dr. Andrew Pinto is supported as a Clinician Scientist by the Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, the Department of Family and Community Medicine, St. Michael’s Hospital, and the Li Ka Shing Knowledge Institute, St. Michael’s Hospital. Dr. Pinto is also supported by a fellowship from the Physicians’ Services Incorporated Foundation and as the Associate Director for Clinical Research at the University of Toronto Practice-Based Research Network (UTOPIAN)

Le syndrome de Lemmierre (étude de deux cas et revue de la littérature)

LE KREMLIN-B.- PARIS 11-BU Méd (940432101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Extreme Winter/Early-Spring Temperature Anomalies in Central Europe

Extreme seasonal fluctuations of the surface-air temperature characterize the climate of central Europe, 45-60 deg North Temperature difference between warm 1990 and cold 1996 in the January-March period, persisting for more than two weeks at a time, amounted to 18 C for extensive areas. These anomalies in the surface-air temperature stem in the first place from differences in the low level flow from the eastern North-Atlantic: the value of the Index 1na of southwesterlies over the eastern North-Atlantic was 8.0 m/s in February 1990, but only 2.6 m/ s in February 1996. The primary forcing by warm advection to positive anomalies in monthly mean surface temperature produced strong synoptic-scale uplift at the 700 mb level over some regions in Europe. The strong uplift contributed in 1990 to a much larger cloud-cover over central Europe, which reduced heat-loss to space (greenhouse effect). Thus, spring arrived earlier than usual in 1990, but later than usual in 1996

Sahaj Samadhi Meditation versus a Health Enhancement Program for depression in chronic pain: protocol for a randomized controlled trial and implementation evaluation

Abstract Background Despite the high prevalence of comorbid chronic pain and depression, this comorbidity remains understudied. Meditation has demonstrated efficacy for both chronic pain and depression independently, yet there have been few studies examining its effectiveness when both conditions are present concurrently. Furthermore, while meditation is generally accepted as a safe and effective health intervention, little is known about how to implement meditation programs within or alongside the health care system. Methods We will conduct a hybrid type 1 effectiveness–implementation evaluation. To measure effectiveness, we will conduct a randomized controlled trial comparing Sahaj Samadhi Meditation and the Health Enhancement Program in 160 people living with chronic pain, clinically significant depressive symptoms, and on long-term opioid therapy. Changes in depressive symptoms will be our primary outcome; pain severity, pain-related function, opioid use, and quality of life will be the secondary outcomes. The primary end point will be at 12 weeks with a secondary end point at 24 weeks to measure the sustainability of acute effects. Patients will be recruited from a community-based chronic pain clinic in a large urban center in Mississauga, Canada. The meditation program will be delivered in the clinical environment where patients normally receive their chronic pain care by certified meditation teachers who are not regulated health care providers. We will use a mixed-methods design using the multi-level framework to understand the implementation of this particular co-location model. Discussion Results of this hybrid evaluation will add important knowledge about the effectiveness of meditation for managing depressive symptoms in people with chronic pain. The implementation evaluation will inform both effectiveness outcomes and future program development, scalability, and sustainability. Trial registration ClinicalTrials.gov: NCT04039568. Registered on 31 July 2019